Emerging data reveals that retatrutide, a dual-action medication, might represent a considerable improvement in weight reduction . This drug combines the effects of a GLP-1 agonist and a GIP receptor , potentially offering a more benefit than available approaches . Study trials have demonstrated positive results , including considerable reductions